GE Healthcare Integrates Covidien NellcorTM SpO2 with OxiMaxTM Technology and SatSeconds Alarm Management System into Giraffe® and Panda® Infant Warmers
BOULDER, Colo.--Covidien, a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced the integration of its industry-leading Nellcor™ pulse oximetry with OxiMax™ technology into GE Healthcare Giraffe® and Panda® infant warmers.
Integrating Nellcor SpO2 (blood oxygenation) monitoring, along with the SatSeconds alarm management system, enhances the respiratory support and resuscitation capabilities of GE Giraffe and Panda warmers and helps clinicians safely monitor and screen infants for life-threatening cardiac and respiratory complications, as well as standardize resuscitation protocols across the perinatal care area.
Each year an estimated 400,000 infants1 born in the United States – 10 percent of the four million born every year2 – require some assistance in the delivery room. Intensive resuscitation is required in one percent of all U.S. deliveries. Fully integrated Nellcor SpO2 monitoring in the GE Giraffe and Panda warmers support the Neonatal Resuscitation Program™ guidelines of the American Academy of Pediatrics and other local and regional resuscitation guidelines. It also helps clinicians effectively address special care and safety needs of infants across NICU and labor and delivery settings by enabling continuous, accurate monitoring of blood oxygenation within minutes of birth, a time when reliable readings can be difficult to obtain.
Blood oxygenation readings are critical because they can provide early warnings of dangerous health conditions and facilitate more rapid clinician response and resuscitation in situations in which every second counts. With Nellcor pulse oximetry integrated into the GE Giraffe and Panda warmer resuscitation and display panel, clinicians can easily monitor blood oxygenation levels of patients.
The warmers also have incorporated Covidien's innovative SatSeconds alarm management feature and support Nellcor SpO2 sensors that are designed for infant care. SatSeconds technology reduces clinically insignificant alarms by 60 percent in NICU settings, helping reduce alarm fatigue among clinicians and creating a quiet environment, which is essential for the developmental care and health of newborns. Nellcor SpO2 adhesive infant and neonatal sensors offer LoSat expanded accuracy, which closely tracks SpO2 values down to 60 percent. And, Nellcor preemie and neonatal non-adhesive sensors provide a convenient, gentle sensor designed for young patients with fragile skin and enable monitoring without damage to the epidermis and the skin's protective functions.
Today's announcement recognizes the ongoing, comprehensive partnership between GE Healthcare and Covidien. The GE Giraffe and Panda warmers with integrated Nellcor SpO2 and SatSeconds alarm management system are the latest example of the long-term, global collaboration jointly announced by GE Healthcare and Covidien in May. This collaboration illustrates the commitment of both companies to deliver innovative clinical measurement technologies that have the potential to support improved care, quality and patient safety.
"For more than 25 years, clinicians have relied on our Nellcor cardiac-based pulse oximetry and sensor portfolio to accurately and safely monitor babies in NICU and labor and delivery departments," said Robert J. White, President, Respiratory and Monitoring Solutions, Covidien. "The ability to incorporate the Nellcor line into existing and new GE Giraffe and Panda infant warmers greatly expands access to our trusted technologies that clinicians can rely on for ensuring the highest standard of infant care."
1. Delivery Room Intervention: Improving the Outcome, Wade D. Rich, RRT, CCRCa, Tina Leone, MDa, Neil N. Finer, MDb
2. Centers for Disease Control and Prevention; see: http://www.cdc.gov/nchs/fastats/births.htm
Panda and Giraffe are U.S. registered trademarks of GE Healthcare or its affiliates or licensors.
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.